Among the 54 subjects that received active treatment, lower viral load, lower total mucus weight and a lower AUC symptom score were highly significant when compared to placebo [ 119 ].
← all excerpts
The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics.
1
—
—